This company has been acquired
Aerie Pharmaceuticals Crecimiento futuro
Future controles de criterios 4/6
Información clave
67.5%
Tasa de crecimiento de los beneficios
78.2%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 20.9% |
| Tasa de crecimiento de los ingresos | 19.3% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Alcon to acquire Aerie Pharmaceuticals at ~$770M, enhancing its ophthalmic pharmaceutical portfolio
Aug 23Aerie Pharmaceuticals grants 16.9K stock options
Aug 15Aerie Pharma rises 14% after Q2 result beat on higher glaucoma franchise sales
Aug 05Aerie Pharma completes enrollment in first Phase 3 trial of netarsudil in Japan
Jun 17Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability
Feb 27
Who Has Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares?
Jan 28Aerie Pharmaceuticals receives European approval for Roclanda
Jan 11Aerie Pharmaceuticals (NASDAQ:AERI) Share Prices Have Dropped 76% In The Last Three Years
Dec 24Is Aerie Pharmaceuticals (NASDAQ:AERI) A Risky Investment?
Nov 28
European advisory group backs Aerie Pharma's Roclanda
Nov 13Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2024 | 226 | -26 | -2 | 41 | 8 |
| 12/31/2023 | 180 | -64 | -56 | 6 | 10 |
| 12/31/2022 | 138 | -123 | -89 | -1 | 5 |
| 9/30/2022 | 214 | -37 | 3 | 7 | N/A |
| 6/30/2022 | 207 | -49 | -5 | 0 | N/A |
| 3/31/2022 | 201 | -69 | -11 | -7 | N/A |
| 12/31/2021 | 194 | -75 | -102 | -99 | N/A |
| 9/30/2021 | 104 | -166 | -50 | -47 | N/A |
| 6/30/2021 | 95 | -166 | -53 | -50 | N/A |
| 3/31/2021 | 86 | -176 | -56 | -53 | N/A |
| 12/31/2020 | 83 | -183 | -68 | -65 | N/A |
| 9/30/2020 | 83 | -192 | -127 | -114 | N/A |
| 6/30/2020 | 82 | -202 | -142 | -130 | N/A |
| 3/31/2020 | 79 | -201 | -158 | -144 | N/A |
| 12/31/2019 | 70 | -200 | -168 | -150 | N/A |
| 9/30/2019 | 60 | -196 | -165 | -155 | N/A |
| 6/30/2019 | 48 | -232 | -175 | -160 | N/A |
| 3/31/2019 | 35 | -240 | -188 | -160 | N/A |
| 12/31/2018 | 24 | -233 | -184 | -153 | N/A |
| 9/30/2018 | 10 | -240 | -196 | -147 | N/A |
| 6/30/2018 | 2 | -187 | -172 | -125 | N/A |
| 3/31/2018 | N/A | -160 | -144 | -109 | N/A |
| 12/31/2017 | N/A | -145 | -120 | -93 | N/A |
| 9/30/2017 | N/A | -116 | -97 | -86 | N/A |
| 6/30/2017 | N/A | -107 | -93 | -86 | N/A |
| 3/31/2017 | N/A | -102 | -91 | -85 | N/A |
| 12/31/2016 | N/A | -99 | -85 | -80 | N/A |
| 9/30/2016 | N/A | -90 | -78 | -75 | N/A |
| 6/30/2016 | N/A | -84 | N/A | -66 | N/A |
| 3/31/2016 | N/A | -80 | N/A | -62 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: AERI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Beneficios vs. Mercado: AERI is forecast to become profitable over the next 3 years, which is considered above average market growth.
Beneficios de alto crecimiento: AERI is expected to become profitable in the next 3 years.
Ingresos vs. Mercado: AERI's revenue (19.3% per year) is forecast to grow faster than the US market (6.9% per year).
Ingresos de alto crecimiento: AERI's revenue (19.3% per year) is forecast to grow slower than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if AERI's Return on Equity is forecast to be high in 3 years time